Olezarsen

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameOlezarsen
Drug Alias NameOlezarsen sodiumGalNAc3 conjugated antisense oligonucleotideTRYNGOLZAISIS- 678354IONIS-APOCIII-LRx +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApolipoprotein C-III inhibitorsRNA modulators
TargetsRibonucleic AcidApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaHyperlipoproteinemia Type IAtherosclerosis +[4] 
Global Approved IndicationsHyperlipoproteinemia Type I
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/19
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCellastra Pharma IncIonis Pharmaceuticals IncSwedish Orphan Biovitrum Ab (Publ) +[4] 
Inactive CompaniesAkcea Therapeutics Inc
Active IndicationsHypertriglyceridemiaHyperlipoproteinemia Type IAtherosclerosis
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG